Skip Navigation


Annals of Oncology Advance Access originally published online on October 11, 2005
Annals of Oncology 2005 16(12):1898-1905; doi:10.1093/annonc/mdi406
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
16/12/1898    most recent
mdi406v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (27)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Machiels, J.-P.
Right arrow Articles by Sempoux, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Machiels, J.-P.
Right arrow Articles by Sempoux, C.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2005 European Society for Medical Oncology

Phase II study of preoperative oxaliplatin, capecitabine and external beam radiotherapy in patients with rectal cancer: the RadiOxCape study

J.-P. Machiels1,*, L. Duck1, B. Honhon2, B. Coster2, J.-C. Coche3, P. Scalliet1, Y. Humblet1, S. Aydin1, J. Kerger4, V. Remouchamps5, J.-L. Canon6, P. Van Maele7, L. Gilbeau8, S. Laurent1, C. Kirkove9, M. Octave-Prignot9, J.-F. Baurain1, A. Kartheuser1 and C. Sempoux1

1 Clinique des Pathologies Tumorales du Colon et du Rectum, Centre du Cancer, Université Catholique de Louvain, Brussels; 2 Service d'Oncologie et de Radiothérapie, Hôpital St-Joseph, Gilly; 3 Service de Gastroentérologie, Clinique St-Pierre, Ottignies; 4 Service d'Oncologie, Cliniques Universitaires de Mont-Godinne (UCL) and Clinique St-Elisabeth, Namur; 5 Service de Radiothérapie, Clinique St-Elisabeth, Namur; 6 Service d'Oncologie, Clinique Notre-Dame, Charleroi; 7 Service de Gastroentérologie, Clinique Saint-Jean, Brussels; 8 Service de Radiothérapie, Hôpital de Jolimont, Haine-St-Paul; 9 Service de Radiothérapie, Cliniques Universitaires Saint-Luc, Brussels, Belgium

* Correspondence to: Dr J.-P. Machiels, Medical Oncology Unit, Université Catholique de Louvain, Cliniques Universitaires Saint-Luc, 10 avenue Hippocrate, 1200 Brussels, Belgium. Tel: +32-2-764-54-85; Fax: +32-2-764-54-28; E-mail: jean-pascal.machiels{at}onco.ucl.ac.be

Background: Preoperative radiotherapy has been shown to decrease the local recurrence rate of patients with locally advanced rectal cancer. Capecitabine and oxaliplatin are both active anticancer agents in the treatment of patients with advanced colorectal cancer and have radiosensitizing properties. Therefore, these drugs would be expected to improve effectiveness of preoperative radiotherapy in terms of local control and prevention of distant metastases.

Patients and methods: Forty patients with rectal cancer (T3–T4 and/or N+) received radiotherapy (1.8 Gy, 5 days a week over 5 weeks, total dose 45 Gy, 3D conformational technique) in combination with intravenous oxaliplatin 50 mg/m2 once weekly for 5 weeks and oral capecitabine 825 mg/m2 twice daily on each day of radiation. Surgery was performed 6–8 weeks after completion of radiotherapy. The main end points were safety and efficacy as assessed by the pathological complete response (pCR).

Results: The most frequent grade 3/4 adverse event was diarrhea, occurring in 30% of patients. pCR was found in five (14%) patients. According to Dworak's classification, good regression was found in six (18%) additional patients.

Conclusions: Combination of preoperative radiotherapy with capecitabine and oxaliplatin is feasible for downstaging rectal cancer.

Key words: capecitabine, oxaliplatin, preoperative, radiotherapy, rectal cancer


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 JCOHome page
C. Fernandez-Martos, C. Pericay, J. Aparicio, A. Salud, M. Safont, B. Massuti, R. Vera, P. Escudero, J. Maurel, E. Marcuello, et al.
Phase II, Randomized Study of Concomitant Chemoradiotherapy Followed by Surgery and Adjuvant Capecitabine Plus Oxaliplatin (CAPOX) Compared With Induction CAPOX Followed by Concomitant Chemoradiotherapy and Surgery in Magnetic Resonance Imaging-Defined, Locally Advanced Rectal Cancer: Grupo Cancer de Recto 3 Study
J. Clin. Oncol., February 10, 2010; 28(5): 859 - 865.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
C. Carlomagno, A. Farella, L. Bucci, F. P. D'Armiento, G. Pesce, S. Pepe, L. Cannella, R. Pacelli, A. De Stefano, R. Solla, et al.
Neo-adjuvant treatment of rectal cancer with capecitabine and oxaliplatin in combination with radiotherapy: a phase II study
Ann. Onc., May 1, 2009; 20(5): 906 - 912.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
C. T. Garnett, J. Schlom, and J. W. Hodge
Combination of Docetaxel and Recombinant Vaccine Enhances T-Cell Responses and Antitumor Activity: Effects of Docetaxel on Immune Enhancement
Clin. Cancer Res., June 1, 2008; 14(11): 3536 - 3544.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
C. G. Willett, B. G. Czito, and J. C. Bendell
Radiation Therapy in Stage II and III Rectal Cancer
Clin. Cancer Res., November 15, 2007; 13(22): 6903s - 6908s.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
J-P Machiels, C Sempoux, P Scalliet, J-C Coche, Y Humblet, E Van Cutsem, J Kerger, J-L Canon, M Peeters, S Aydin, et al.
Phase I/II study of preoperative cetuximab, capecitabine, and external beam radiotherapy in patients with rectal cancer
Ann. Onc., April 1, 2007; 18(4): 738 - 744.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
C. Rodel, T. Liersch, R. M. Hermann, D. Arnold, T. Reese, M. Hipp, A. Furst, N. Schwella, M. Bieker, G. Hellmich, et al.
Multicenter Phase II Trial of Chemoradiation With Oxaliplatin for Rectal Cancer
J. Clin. Oncol., January 1, 2007; 25(1): 110 - 117.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
I. Chau, D. Cunningham, D. Tait, and G. Brown
In Reply
J. Clin. Oncol., October 1, 2006; 24(28): 4665 - 4666.
[Full Text] [PDF]

Home page
 Ann OncolHome page
F. A. Calvo, F. J. Serrano, J. A. Diaz-Gonzalez, M. Gomez-Espi, E. Lozano, R. Garcia, D. de la Mata, J. A. Arranz, P. Garcia-Alfonso, G. Perez-Manga, et al.
Improved incidence of pT0 downstaged surgical specimens in locally advanced rectal cancer (LARC) treated with induction oxaliplatin plus 5-fluorouracil and preoperative chemoradiation
Ann. Onc., July 1, 2006; 17(7): 1103 - 1110.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
M. G. Fakih
Concurrent oxaliplatin, capecitabine, and radiation therapy in the neoadjuvant therapy of rectal adenocarcinoma: can we get the right dose first?
Ann. Onc., June 1, 2006; 17(6): 1029 - 1030.
[Full Text] [PDF]

Home page
 Ann OncolHome page
J.-P. Machiels and P. Scalliet
Reply to Letter to the Editor 'Concurrent oxaliplatin, capecitabine, and radiation therapy in the neoadjuvant therapy of rectal adenocarcinoma: can we get the right dose first?', by M. G. Fakih (Ann Oncol 2006; 17: 1029)
Ann. Onc., June 1, 2006; 17(6): 1030 - 1031.
[Full Text] [PDF]

Home page
 JCOHome page
J.-P. Machiels, S. Aydin, M.-A. Bonny, F. Hammouch, and C. Sempoux
What Is the Best Way to Predict Disease-Free Survival After Preoperative Radiochemotherapy for Rectal Cancer Patients: Tumor Regression Grading, Nodal Status, or Circumferential Resection Margin Invasion?
J. Clin. Oncol., March 10, 2006; 24(8): 1319 - 1319.
[Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.